市场调查报告书
商品编码
1642444
2025-2033 年按定序类型、产品类型、技术、应用、最终用户和地区分類的下一代定序市场报告Next-Generation Sequencing Market Report by Sequencing Type, Product Type, Technology, Application, End-User, and Region 2025-2033 |
2024年,全球次世代定序( IMARC Group )市场规模达233亿美元。由于技术的不断进步、临床应用的增加、对生物资讯工具和资料分析解决方案的需求不断增加、对精准医疗的日益关注以及研发力度的加强,NGS 市场正在迅速扩大。
新一代定序 (NGS) 是一种平行定序技术,可确定脱氧核糖核酸 (DNA) 部分中的核苷酸序列。它涉及多种程序,例如合成定序(SBS)和离子半导体、单分子即时定序(SMRT)和奈米孔定序。它是一种经济高效的解决方案,可帮助医疗专业人员以高精度和高速度获得精确的结果。它还促进临床诊断、个人化和遗传医学以及农业和动物研究领域的研究。目前,它被用于药物基因组学以升级药物递送过程。
全球老年人口不断增长,癌症、心血管和神经系统疾病等各种慢性疾病的盛行率不断上升,是积极影响市场的关键因素之一。这也可以归因于越来越多地使用遗传图谱来指导科学家分析导致医疗状况的基因。此外,液体活检在癌症诊断中的广泛采用,以及越来越多地利用NGS技术引入非侵入性癌症生物标记进行即时癌症监测和检测,正在创造积极的市场前景。与此一致的是,定序仪的持续技术创新,例如整合云端运算系统以增强资料安全性和管理,正在加强市场成长。除此之外,各国政府为改善医疗基础设施而持续提供的资金也为市场成长提供了动力。此外,领导企业对分子生物学、技术工程和定序化学研发 (R&D) 活动的投资不断增加,带来了良好的市场前景。
全基因组定序
标靶重测序
全外显子定序
RNA定序
晶片测序
从头测序
甲基定序
其他的
由于 NGS 市场上有许多公司提供标靶重测序服务,标靶重测序代表了最大的细分市场。
仪器仪表
试剂及耗材
软体和服务
试剂和耗材代表最常用的产品类型,有助于样品製备、DNA 分离、样品净化、目标富集和品质保证。
合成定序
离子半导体定序
单分子即时定序
奈米孔定序
其他的
合成定序因其在 DNA 定序中的高精度以及在 NGS 仪器中的日益普及而得到了广泛的应用。此外,它还提供最高的无错误吞吐量结果。
生物标记与癌症
药物发现与个人化医疗
基因筛检
诊断
农业和动物研究
其他的
由于癌症盛行率不断上升以及人们对早期诊断和治疗益处的认识不断提高,生物标记和癌症目前在市场上占据主导地位。
学术机构与研究中心
医院和诊所
製药与生物技术公司
其他的
由于NGS解决方案在研究计画中的应用越来越多,学术机构和研究中心占据了大部分市场份额。
北美洲
美国
加拿大
亚太地区
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
由于该地区拥有技术先进的医疗保健研究框架,加上存在多个采用 NGS 提供基因检测服务的临床实验室,北美在市场上表现出明显的主导地位。
该报告还分析了市场的竞争格局,一些主要参与者包括安捷伦科技、Becton Dickinson and Company、10x Genomics、BGI Group、Eurofins Scientific、F. Hoffmann-La Roche AG、Illumina Inc.、Genewiz、Macrogen 、Oxford Nanopore Technologies、Pacific Biosciences、PerkinElmer、Thermo Fisher Scientific、Qiagen NV、GenapSys Inc. 等。
The global next-generation sequencing (NGS) market size reached USD 23.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 85.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15.5% during 2025-2033. The market for NGS is expanding rapidly due to ongoing technological advancements, increasing use in clinical applications, escalating demand for bioinformatics tools and data analysis solutions, a rising focus on precision medicine, as well as enhanced research and development efforts.
Next-generation sequencing (NGS) is a parallel sequencing technology that determines the sequence of nucleotides in a section of the deoxyribonucleic acid (DNA). It involves various procedures, such as sequencing by synthesis (SBS) and ion semiconductor, single-molecule real-time (SMRT), and nanopore sequencing. It is a cost-effective solution that assists medical professionals in achieving precise results with high accuracy and speed. It also facilitates research in the fields of clinical diagnostics, personalized and genetic medicines, and agriculture and animal studies. At present, it is utilized in pharmacogenomics to escalate the drug delivery process.
The growing global geriatric population and the rising prevalence of various chronic medical disorders, such as cancer, cardiovascular, and neurological disorders, represent one of the key factors positively influencing the market. It can also be attributed to the growing use of genetic maps for guiding scientists to analyze the genes that are responsible for medical conditions. In addition, the widespread adoption of liquid biopsies in cancer diagnostics and the increasing utilization of NGS technologies to introduce non-invasive cancer biomarkers for real-time cancer monitoring and detection are creating a positive market outlook. In line with this, continuous technological innovations in sequencers, such as the integration of cloud-computing systems for enhanced data security and management, are strengthening the market growth. Apart from this, continuous financing by governments of various countries to improve healthcare infrastructure is providing a thrust to the market growth. Furthermore, increasing investments by leading players in research and development (R&D) activities for molecular biology, technical engineering, and sequencing chemistry is offering a favorable market outlook.
Whole Genome Sequencing
Targeted Resequencing
Whole Exome Sequencing
RNA Sequencing
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
Others
Targeted resequencing represents the largest market segment due to the presence of numerous companies in the NGS market offering targeted resequencing services.
Instruments
Reagents and Consumables
Software and Services
Reagents and consumables represent the most commonly used product type that assists in sample preparation, DNA isolation, sample cleanup, target enrichment, and quality assurance.
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-Molecule Real-Time Sequencing
Nanopore Sequencing
Others
Sequencing by synthesis finds extensive applications on account of its high accuracy in performing DNA sequencing and its growing incorporation in NGS instrumentation. In addition, it offers the highest yield of error-free throughput results.
Biomarker and Cancer
Drug Discovery and Personalized Medicine
Genetic Screening
Diagnostics
Agriculture and Animal Research
Others
Biomarker and cancer currently dominate the market due to the rising prevalence of cancer and increasing awareness among individuals about the benefits of early diagnosis and treatment.
Academic Institutes & Research Centers
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Others
Academic institutes and research centers account for the majority of the market share due to the increasing application of NGS solutions in research projects.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the availability of a technologically advanced healthcare research framework in the region, coupled with the presence of multiple clinical laboratories that employ NGS to provide genetic testing services.
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.